Where We Are Going Today: Frozen Bucket

Updated 08 March 2019
0

Where We Are Going Today: Frozen Bucket

Frozen Bucket is the perfect place for ice cream lovers, as it offers an experience unlike any other you are likely to find in Jeddah.

Not only does it offer some incredible and unusual flavors, but its ice cream is made the way it was in the old days, hand-churned in a bucket. Each day’s batch is made fresh that morning and only served that day, never stored overnight.

As a result, the available flavors vary from day to day. They include deliciously unusual options such as saffron and apricot, lychee, and watermelon. If you fancy even more variety, try the banana chocolate, Shahi Kulfi or choco pie, among many others.

As the perfect finishing touch, the ice cream is served in pottery dishes that help to keep it cold for longer so that it does not melt too quickly. This small detail is a fresh and innovative idea that adds to the highly enjoyable and unique experience of sampling Frozen Bucket’s icy delights.


Jazz Pharma’s sleep disorder treatment gets US FDA nod

Updated 21 March 2019
0

Jazz Pharma’s sleep disorder treatment gets US FDA nod

  • The drug, solriamfetol, will treat excessive sleepiness in adult patients with narcolepsy or obstructive sleep apnea
  • The patent of Jazz's narcolepsy drug, Xyrem, were declared invalid by a US appeals court in July
The US Food and Drug Administration approved Jazz Pharmaceuticals Plc’s treatment for patients with a form of sleep disorder, the company said on Wednesday.
The drug, solriamfetol, will treat excessive sleepiness in adult patients with narcolepsy or obstructive sleep apnea (OSA).
Solriamfetol is expected to be commercially available in the United States following the final scheduling decision by the Drug Enforcement Administration (DEA), Jazz said in a statement.
The approval comes as Jazz is trying to reduce its reliance on its blockbuster narcolepsy drug, Xyrem, whose patents were declared invalid by a US appeals court in July.
Xyrem is an approved treatment for excessive daytime sleepiness and cataplexy in patients with narcolepsy. It brought in sales of $1.4 billion in 2018 and accounted for about 70 percent of company’s revenue.
“Jazz is trying to reduce its reliance on Xyrem, and solriamfetol will be one of the drugs it plans to launch to do that,” Mizuho Securities USA analyst Irina Koffler said ahead of the agency’s decision.
“Solriamfetol is expected to be an important driver of both diversification and growth,” RBC Capital Markets analyst Randall Stanicky said in a note ahead of the approval.
Solriamfetol is expected to bring in revenue of $314 million by 2024, Stanicky said.
Narcolepsy is a chronic sleep disorder with overwhelming daytime drowsiness and sudden attacks of sleep, while obstructive sleep apnea is a potentially serious sleep disorder that can cause breathing to repeatedly stop and start.
“Narcolepsy is very disabling to people as they often get diagnosed young and stop their education and drop out of high school or college,” Koffler said.
“Sleep apnea is a different problem in the sense that a lot of people don’t know they have it, have trouble breathing at night and they even fall asleep during the day.”